Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Transferring Luminex® cytokine assays to a wall-less plate technology: Validation and comparison study with plasma and cell culture supernatants.

Versteeg L, Le Guezennec X, Zhan B, Liu Z, Angagaw M, Woodhouse JD, Biswas S, Beaumier CM.

J Immunol Methods. 2017 Jan;440:74-82. doi: 10.1016/j.jim.2016.11.003. Epub 2016 Nov 11.

PMID:
27840065
2.

MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.

Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad AS, Ayers M, Nebozhyn M, Loboda A, Hirsch HA, Zhang T, Shi B, Merkel CE, Angagaw MH, Wang Y, Long BJ, Lennon XQ, Miselis N, Pucci V, Monahan JW, Lee J, Kondic AG, Im EK, Mauro D, Blanchard R, Gilliland G, Fawell SE, Zawel L, Schuller AG, Strack P.

PLoS One. 2014 Oct 7;9(10):e108371. doi: 10.1371/journal.pone.0108371. eCollection 2014.

3.

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA.

Cancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24.

4.

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Zhang W, Haines BB, Efferson C, Zhu J, Ware C, Kunii K, Tammam J, Angagaw M, Hinton MC, Keilhack H, Paweletz CP, Zhang T, Winter C, Sathyanarayanan S, Cheng J, Zawel L, Fawell S, Gilliland G, Majumder PK.

Transl Oncol. 2012 Dec;5(6):422-9. Epub 2012 Dec 1.

5.

PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.

Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, Nagashima K, O'Hare E, Erkul Y, Di Bacco A, Gargano D, Shomer NH, Angagaw M, Leccese E, Andrade P, Hurd M, Shin MK, Vogt TF, Northrup A, Bobkova EV, Kasibhatla S, Bronson RT, Scott ML, Draetta G, Richon V, Kohl N, Blume-Jensen P, Andersen JN, Kraus M.

Cancer Res. 2011 Apr 15;71(8):3052-65. doi: 10.1158/0008-5472.CAN-10-2282.

6.

Purine derivatives as potent gamma-secretase modulators.

Rivkin A, Ahearn SP, Chichetti SM, Hamblett CL, Garcia Y, Martinez M, Hubbs JL, Reutershan MH, Daniels MH, Siliphaivanh P, Otte KM, Li C, Rosenau A, Surdi LM, Jung J, Hughes BL, Crispino JL, Nikov GN, Middleton RE, Moxham CM, Szewczak AA, Shah S, Moy LY, Kenific CM, Tanga F, Cruz JC, Andrade P, Angagaw MH, Shomer NH, Miller T, Munoz B, Shearman MS.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2279-82. doi: 10.1016/j.bmcl.2010.02.008. Epub 2010 Feb 6.

PMID:
20207146
7.

Fluorinated piperidine acetic acids as gamma-secretase modulators.

Stanton MG, Hubbs J, Sloman D, Hamblett C, Andrade P, Angagaw M, Bi G, Black RM, Crispino J, Cruz JC, Fan E, Farris G, Hughes BL, Kenific CM, Middleton RE, Nikov G, Sajonz P, Shah S, Shomer N, Szewczak AA, Tanga F, Tudge MT, Shearman M, Munoz B.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):755-8. doi: 10.1016/j.bmcl.2009.11.034. Epub 2009 Nov 13.

PMID:
20005099
8.

Splenectomy normalizes hematocrit in murine polycythemia vera.

Mo JR, Mathur A, Angagaw M, Zhao S, Wang Y, Gargano D, DiBacco A, Bachman ES.

PLoS One. 2009 Sep 30;4(9):e7286. doi: 10.1371/journal.pone.0007286.

9.

Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.

Tammam J, Ware C, Efferson C, O'Neil J, Rao S, Qu X, Gorenstein J, Angagaw M, Kim H, Kenific C, Kunii K, Leach KJ, Nikov G, Zhao J, Dai X, Hardwick J, Scott M, Winter C, Bristow L, Elbi C, Reilly JF, Look T, Draetta G, Van der Ploeg L, Kohl NE, Strack PR, Majumder PK.

Br J Pharmacol. 2009 Nov;158(5):1183-95. doi: 10.1111/j.1476-5381.2009.00389.x. Epub 2009 Sep 23.

10.

Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.

Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M, Laskey J, Bettano KA, Kasibhatla S, Reilly JF, Sur C, Majumder PK.

Cancer Res. 2009 Sep 15;69(18):7466-72. doi: 10.1158/0008-5472.CAN-08-4385. Epub 2009 Sep 8.

11.

A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models.

Haines BB, Bettano KA, Chenard M, Sevilla RS, Ware C, Angagaw MH, Winkelmann CT, Tong C, Reilly JF, Sur C, Zhang W.

Neoplasia. 2009 Jan;11(1):39-47.

Supplemental Content

Loading ...
Support Center